research use only
Cat.No.S7397
| Related Targets | ERK p38 MAPK JNK MEK Ras KRas S6 Kinase MAP4K TAK1 Mixed Lineage Kinase |
|---|---|
| Other Raf Inhibitors | LY3009120 Exarafenib (KIN-2787) GDC-0879 Avutometinib (Ro5126766, CH5126766) PLX-4720 AZ 628 SB590885 TAK-632 GW5074 RAF265 (CHIR-265) |
|
In vitro |
DMSO
: 92 mg/mL
(197.92 mM)
Water : Insoluble Ethanol : Insoluble The solubility data above are all experimental results (not literature values). |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Read more about Sorafenib (BAY 43-9006) solubility in DMSO or water
Read more about Sorafenib (BAY 43-9006) working concentrations for cell culture treatment
Sorafenib (BAY 43-9006) is a potent inhibitor of VEGFR-2 kinase (0.22±0.09 mM), VEGFR-2 (0.84 mM), VEGFR2 kinase (8.99 nM), EGFR kinase (0.76 mgm L−1), RAF1 (6 nM). Sorafenib (BAY 43-9006) exhibits the greatest inhibitory potency toward RAF1 (IC50 = 6 nM).
| Information | Sorafenib is an ATP-competitive multikinase inhibitor. It affects MAPK signaling by blocking ATP sites, inhibiting tumor growth. |
|---|---|
|
Read more about Sorafenib (BAY 43-9006) IC50 for cell-based and cell-free assays |
|
| Primary Applications and Mechanism of Action | |
| Molecular Weight | 464.82 | Formula | C21H16ClF3N4O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 284461-73-0 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | NSC-724772,BAY 43-9006 | Smiles | CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F | ||
Read more comparative analysis about Sorafenib (BAY 43-9006)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.